Affimed
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Affimed sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Affimed: 7 sponsored US clinical trials, none currently recruiting.
Affimed sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Transformed Mycosis Fungoides, with 1 trials.
Upper-quartile sponsor footprint
Affimed sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
NCT05883449
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
NCT05109442
Study to Assess AFM24 in Advanced Solid Cancers
NCT04259450
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
NCT04101331
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02665650
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
NCT02106091
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
NCT01221571
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
Therapeutic Areas
How the Affimed early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 3 completed (43%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Transformed Mycosis Fungoides (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Affimed: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Affimed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Affimed page
7 registered trials is a research-attention snapshot, not an endorsement of Affimed or any single study.
- None of Affimed's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Transformed Mycosis Fungoides is the condition Affimed studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transformed Mycosis Fungoides trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Affimed pipeline card: 7 registered trials from official public datasets.Report a data error.